Additionally, CCR5 antagonist reduces inflammatory mediators such as GM-CSF/iNOS and MCP-1/TNF-α in EAE; this points to the potential benefits of CCR5 antagonist as a novel therapeutic target for the treatment of MS. Here, NOS2 is linked to myeloid sarcoma.